Jeffrey Cleland

Dr. Cleland has 30 years of industry experience in research and development, including more than a decade at Genentech, Inc. His experience in startups includes major roles in obtaining more than $500 million in capital at stages from Series A through E and exit via IPO including over $400 million in capital raised as CEO. As the founding CEO of Versartis (VSAR), he led one of top biotech IPOs of all time. He also led the Series B financing and clinical translation of novel Johns Hopkins University technology as CEO of Graybug Vision (GRAY). He held important leadership roles in the successful approval of two drugs, Herceptin® and Nutropin Depot®, as well as in early work on Lucentis®, Avastin®, and Kadcyla®. He holds a PhD in Chemical Engineering from MIT. Dr. Cleland has authored more than 100 articles and four books and an inventor on over 20 issued patents. He serves on the Boards of BIO, Exicure, and Zylem Biosciences.